Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Medinotec (MDNC) Cash & Equivalents (2022 - 2025)

Medinotec filings provide 4 years of Cash & Equivalents readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 6.74% to $2.9 million in Q4 2025 year-over-year; TTM through Nov 2025 was $2.9 million, a 6.74% increase, with the full-year FY2025 number at $2.8 million, down 1.4% from a year prior.
  • Cash & Equivalents hit $2.9 million in Q4 2025 for Medinotec, up from $2.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $3.6 million in Q2 2022 to a low of $131577.0 in Q1 2022.
  • Median Cash & Equivalents over the past 4 years was $2.8 million (2024), compared with a mean of $2.6 million.
  • The widest YoY moves for Cash & Equivalents: up 2048.9% in 2023, down 23.93% in 2023.
  • Medinotec's Cash & Equivalents stood at $2.8 million in 2022, then decreased by 5.9% to $2.7 million in 2023, then decreased by 0.08% to $2.7 million in 2024, then increased by 6.74% to $2.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $2.9 million (Q4 2025), $2.2 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.